Oxybutynin Chloride

Antimuscarinic / Anticholinergic Smooth Muscle Relaxant (Urinary Antispasmodic)

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 0.2-0.5 mg/kg q8-12h Duration: Variable; often long-term for chronic conditions
Notes: Start at the lower end of the dose range and titrate to effect. Maximum dose in dogs is typically 15 mg/day. Administer with food to reduce gastrointestinal upset.
Cat PO 0.5-1 mg per cat (approximately 0.1-0.2 mg/kg) q12h Duration: Variable; often long-term
Notes: Cats are sensitive to anticholinergic effects; use with caution. Compounded formulations may be needed for accurate dosing.
Horse PO Not established; anecdotal doses of 0.5-1 mg/kg q12h have been reported q12h Duration: Variable
Notes: Limited evidence; use only if other therapies fail and under close veterinary supervision.
Rabbit PO 0.5-1 mg/kg q12h Duration: Variable
Notes: Use with caution; monitor for gastrointestinal stasis.

Clinical Indications & Species Uses

General Indications
  • Symptomatic treatment of detrusor overactivity and urinary incontinence in small animals
Dog (Canine)
  • Management of detrusor hyperreflexia (overactive bladder)
  • Treatment of urinary incontinence due to urethral sphincter hypotonus (off-label)
  • Reduction of bladder spasms associated with cystitis or urolithiasis
  • Adjunct in the management of detrusor instability
Cat (Feline)
  • Management of detrusor hyperreflexia (overactive bladder)
  • Treatment of urinary incontinence (off-label)
  • Reduction of bladder spasms associated with feline interstitial cystitis (off-label)

Pharmacology & Mechanism of Action

Drug Class: Antimuscarinic / Anticholinergic | Pharmacological Group: Smooth Muscle Relaxant (Urinary Antispasmodic)

Mechanism of Action: Oxybutynin chloride is a tertiary amine antimuscarinic agent that competitively antagonizes acetylcholine at postganglionic muscarinic receptors (M2 and M3 subtypes) on smooth muscle cells of the urinary bladder. By blocking cholinergic stimulation, it reduces detrusor muscle contractility, increases bladder capacity, and decreases the frequency and amplitude of uninhibited contractions. Additionally, it exhibits direct smooth muscle relaxant (spasmolytic) effects and local anesthetic properties, which contribute to its therapeutic action in overactive bladder and detrusor instability.

Pharmacodynamics: Oxybutynin produces a dose-dependent reduction in detrusor pressure and an increase in bladder volume at first contraction. It also delays the urge to void and reduces urinary frequency. The drug's antimuscarinic effects are relatively selective for the bladder, but at higher doses, systemic anticholinergic effects (e.g., dry mouth, constipation, tachycardia) become apparent. In veterinary patients, the pharmacodynamic response is variable, and clinical efficacy may require dose titration.

⚡ Pharmacokinetics Summary

Absorption: Oxybutynin is well absorbed from the gastrointestinal tract after oral administration. However, first-pass metabolism in the liver is extensive, resulting in low systemic bioavailability of the parent drug. The active metabolite, N-desethyloxybutynin, contributes significantly to both therapeutic and adverse effects. Food may alter absorption, but the clinical significance is minimal.
Distribution: Oxybutynin is widely distributed throughout the body, with high concentrations in the liver, lungs, and kidneys. It crosses the blood-brain barrier, which may contribute to central nervous system effects (e.g., sedation, confusion) in some animals. The volume of distribution is moderate, and protein binding is approximately 91-93% in humans; similar binding is expected in animals.
Metabolism: Oxybutynin undergoes extensive hepatic metabolism, primarily via the cytochrome P450 enzyme CYP3A4, to form the active metabolite N-desethyloxybutynin. This metabolite has similar antimuscarinic activity and may be responsible for a significant portion of the drug's effects. Other minor metabolites are inactive.
Excretion: Oxybutynin and its metabolites are excreted primarily in the urine, with less than 1% of the parent drug excreted unchanged. Biliary excretion also occurs. The elimination half-life in dogs is approximately 1-2 hours for the parent drug, but the active metabolite may have a longer half-life.
Half-Life: Dogs: 1-2 hours (parent drug); Cats: not well documented, likely similar or slightly longer; Humans: 2-3 hours (immediate-release).
Bioavailability: Oral bioavailability is low (approximately 6% in humans) due to extensive first-pass metabolism; in dogs, it is reported to be around 5-10%.
Protein Binding: Approximately 91-93% (in humans; likely similar in animals).

Available Formulations & Strengths

Oral Tablet (immediate-release) 5 mg (PO)
Oral Tablet (extended-release) 5 mg, 10 mg, 15 mg (PO)
Oral Syrup 5 mg/5 mL (PO)
Transdermal Gel (human product; not commonly used in veterinary medicine) 100 mg/gram (gel) (Topical)

Contraindications & Clinical Warnings

Contraindications:
  • Hypersensitivity to oxybutynin or any component of the formulation
  • Uncontrolled narrow-angle glaucoma
  • Urinary retention (e.g., due to urethral obstruction)
  • Gastric retention or severe gastrointestinal obstruction
  • Myasthenia gravis
  • Severe hepatic or renal impairment (use with caution)
  • Tachyarrhythmias or unstable cardiovascular disease
Warnings & Clinical Precautions:
  • Use with caution in animals with autonomic neuropathy, gastrointestinal motility disorders, or hiatal hernia.
  • May exacerbate signs of hyperthyroidism, coronary heart disease, congestive heart failure, or hypertension.
  • In cats, anticholinergic effects may be more pronounced; monitor for constipation, urinary retention, and mydriasis.
  • Use with caution in geriatric animals due to increased risk of CNS effects (e.g., sedation, confusion).
  • In animals with renal or hepatic impairment, dose adjustment may be necessary.
  • Do not crush or chew extended-release tablets; administer whole.
  • Safety in pregnant or lactating animals has not been established; use only if clearly needed.

Adverse Effects & Reactions

Common:

  • Dry mouth
  • Constipation
  • Urinary retention
  • Mydriasis
  • Blurred vision
  • Sedation
  • Gastrointestinal upset (vomiting, diarrhea)

Serious / Severe:

  • Severe allergic reactions (anaphylaxis)
  • Cardiac arrhythmias (tachycardia, palpitations)
  • CNS excitation or confusion (especially in cats)
  • Heat stroke due to decreased sweating (rare in animals)

Rare:

  • Hallucinations
  • Seizures
  • Hepatotoxicity
  • Bone marrow suppression

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Other anticholinergic drugs (e.g., atropine, glycopyrrolate) Additive anticholinergic effects, increased risk of severe constipation, urinary retention, and tachycardia. High
CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin) May increase oxybutynin plasma concentrations, leading to enhanced effects and toxicity. Moderate
CYP3A4 inducers (e.g., phenobarbital, rifampin) May decrease oxybutynin plasma concentrations, reducing efficacy. Moderate
Cholinesterase inhibitors (e.g., neostigmine, pyridostigmine) Antagonistic effects; may reduce the efficacy of either drug. Moderate
Tricyclic antidepressants (e.g., amitriptyline) Additive anticholinergic and sedative effects. Moderate
Digoxin May increase digoxin absorption due to reduced gastrointestinal motility, leading to increased digoxin levels. Mild

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe anticholinergic effects: dry mouth, mydriasis, flushed skin, hyperthermia, tachycardia, urinary retention, ileus, agitation, confusion, hallucinations, seizures, respiratory depression, coma

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Induce emesis if recent ingestion and the animal is conscious. Administer activated charcoal to reduce absorption. Provide supportive care including IV fluids, temperature management, and cardiovascular monitoring. Physostigmine (0.02-0.04 mg/kg IV) may be used to reverse severe central anticholinergic effects, but use with caution due to risk of bradycardia and seizures. Diazepam or barbiturates may be used for seizures. In severe cases, consider gastric lavage.

Food Animal Withdrawal Times

Oxybutynin is not approved for use in food animals. Withdrawal times have not been established. Do not use in animals intended for human consumption.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25°C, excursions permitted to 15-30°C).

Handling & Special Conditions: Protect from moisture. Keep container tightly closed. Do not freeze oral syrup.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human use in the US; not FDA-approved for veterinary use, but may be prescribed legally as an extra-label drug by veterinarians.

Extra-Label (Off-Label) Use: In the US, extra-label use in animals is permitted under the Animal Medicinal Drug Use Clarification Act (AMDUCA) provided there is a valid veterinarian-client-patient relationship, and the drug is not prohibited in food animals. However, oxybutynin is not approved for veterinary use, and its use in food animals is not recommended due to lack of withdrawal data.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Oxybutynin is primarily used in small animal practice for managing urinary incontinence and overactive bladder. It is often considered a second-line therapy after dietary management and other medications (e.g., phenylpropanolamine for sphincter hypotonus). Clinical response is variable, and dose titration is essential. In dogs, it may be combined with phenylpropanolamine for refractory cases. In cats, it is used cautiously due to increased sensitivity to anticholinergic effects. Extended-release formulations may improve compliance but should not be crushed. Monitor for adverse effects, especially constipation and urinary retention. In animals with pre-existing cardiovascular disease, use with caution. Always obtain a thorough history and rule out urinary tract infections or obstructions before initiating therapy.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)